Navigation Links
Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients
Date:8/20/2012

By Denise Mann
HealthDay Reporter

MONDAY, Aug. 20 (HealthDay News) -- People with psoriasis who take a new class of drugs known as tumor necrosis factor (TNF) inhibitors may be at a lower risk for heart attack than their counterparts who only use topical medications to treat this inflammatory skin condition, a new study shows.

And patients taking older systemic medicines and phototherapy may also have a reduced heart attack risk compared to those using topical preparations, the study found.

Of 8,845 study participants, about 57 percent were treated with topical therapy only, 19 percent received a TNF inhibitor for at least two months and about 24 percent were treated with other medications or phototherapy. People who were treated with TNF inhibitors had a 50 percent lower risk, and those treated with other psoriasis drugs or phototherapy had a 46 percent lower risk for heart attack, than those who used topical medications alone.

The findings appear online Aug. 20 in the Archives of Dermatology.

TNF inhibitors, or blockers, are part of a class of drugs called biologics. They work by blocking key players in the inflammation cascade. Phototherapy uses laser or ultraviolet light to slow the rapidly growing skin cells that lead to psoriasis.

Psoriasis is marked by raised, reddish and itchy skin patches or plaques that may be covered with a silvery-white coating. Still, psoriasis is more than skin deep. People with this condition are at higher risk for developing heart attacks, strokes and certain types of cancer. This is likely related to underlying inflammation.

The new study can't say how, or even if, TNF blockers lower heart risks in people with psoriasis. "We know that reducing inflammation reduces risk of diabetes and other inflammatory processes, which could reduce risk for heart attack and stroke," said study author Dr. Jashin Wu, at the Kaiser Permanente Los Angeles Medical Center.

One group of study patients took TNF blockers etanercept (Enbrel), infliximab (Remicade) or adalimumab (Humira).

Other patients randomly assigned to a second group received either oral medicines -- cyclosporine, acitretin or methotrexate -- or phototherapy. The third group received topical medications alone.

TNF blockers have changed the treatment of psoriasis and other inflammatory diseases such as rheumatoid arthritis, but they do have their share of side effects including infection and certain types of cancer. "In psoriasis, the immune system is hyperactive so we try to reduce it, but anytime you lower immune activity, there is always the risk of infection or reactivation of a latent infection," Wu said.

Not everyone with psoriasis does or should take biologic medications. "I usually determine the severity of the psoriasis first," he said. "If 10 percent of their body is covered or if they have psoriatic arthritis and/or have failed other medications, they are eligible," he said.

These drugs are not inexpensive; a November 2011 study in Arthritis & Rheumatism found that for patients taking various TNF drugs for psoriatic arthritis, costs ranged from about $13,500 to nearly $25,000 per year.

The study findings are welcome news, said Dr. Bruce Strober, an associate professor of dermatology at the University of Connecticut in Farmington.

"There is previous and well-replicated evidence that patients with [rheumatoid arthritis] treated successfully with TNF inhibitors demonstrate a lowered risk of heart attack, and perhaps even heart failure. But similar data in psoriasis have been lacking," he said. "This analysis is the first demonstration that, potentially, the use of TNF inhibitors may prevent heart attacks in psoriasis patients."

Still, Strober said, "these data must be viewed as preliminary and not conclusive, as more studies from different source databases must replicate and confirm these findings."

TNF-inhibitors should be viewed broadly as "anti-inflammatory" drugs, he said. "Psoriasis is an inflammatory disease of not only the skin but also multiple other organs, including the joints, ligaments, tendons, and the blood vessels," he explained. "TNF-inhibitors therefore reduce inflammation of the blood vessels, and therefore block a root cause of [heart disease]."

More information

Learn all about psoriasis at the American Academy of Dermatology.

SOURCES: Bruce Strober, M.D., associate professor, dermatology, University of Connecticut, Farmington, Conn.; Jashin J. Wu, M.D., Kaiser Permanente Los Angeles Medical Center, Calif.; Aug. 20, 2012, Archives of Dermatology, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Antidepressants May Be Safe for Parkinsons Patients
2. Newer Second-Line Diabetes Drug May Outperform Older Meds
3. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
4. Newer technology to control blood sugar works better than conventional methods
5. Newer hip reconstruction technique provides good outcomes for athletes
6. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
7. Older Antipsychotics May Work as Well as Newer Ones: Review
8. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
9. Gene Behind Psoriasis Identified, Researchers Say
10. Vigorous Exercise Might Keep Psoriasis at Bay
11. Could Psoriasis Increase Odds for Type 2 Diabetes?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Psoriasis Drugs May Lower Heart Attack Risk for Patients 
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
Breaking Medicine Technology: